| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_56820bbb13a42311271e147869a36d30 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y603-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-9015 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57438 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate |
2013-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2015-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_98c51aa4d2bfc6099f09f7ad868bda12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fbfd6997511d82bc7d8acbbb7d9f29c5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c4aeb18bad4e15dfaea3511d2e2bb3d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78d6058fb4fefff6f9e63ee80323ee3d |
| publicationDate |
2015-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-101517692-B1 |
| titleOfInvention |
Method for screening therapeutic agent of liver cancer by inducing HBx degradation via stabilization of MARCH5 expression |
| abstract |
The present invention relates to a screening method for treating liver cancer, which induces degradation of hepatitis B virus X protein (HBx) through stabilization of mitochondrial E3 ubiquitin ligase (MARCH5) expression. Constructing a liver cancer cell line expressing Mitochondrial E3 Ubiquitin Ligase (MARCH5); (2) contacting the test substance to the liver cancer cell line constructed in the step (1) and measuring the degree of MARCH5 expression; (3) expressing hepatitis B virus X protein (HBx) and measuring the level of MARCH5 expression in the liver cancer cell line constructed in the step (1); And (4) selecting a test substance whose MARCH5 expression level measured in step (2) is higher than that of the control group, using the degree of MARCH5 expression measured in step (3) as a control group, . |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110478485-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110478485-A |
| priorityDate |
2013-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |